What is Insight Molecular Diagnostics Quick Ratio?
Insight Molecular DiagnosticsIMDX -0.19%49 Quick Ratio is 2.51 as of Mar. 2026, which is 3% below its 10-year median of 2.58. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 63.26% on this metric.
Insight Molecular Diagnostics has a quick ratio of 2.51. It generally indicates good short-term financial strength.
The historical rank and industry rank for Insight Molecular Diagnostics's Quick Ratio or its related term are showing as below:
IMDX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.5 Med: 2.58 Max: 12.82
Current: 2.51
During the past 13 years, Insight Molecular Diagnostics's highest Quick Ratio was 12.82. The lowest was 0.50. And the median was 2.58.
IMDX's Quick Ratio is ranked better than 63.26% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.67
vs IMDX: 2.51
Insight Molecular Diagnostics (NAS:IMDX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Insight Molecular Diagnostics Quick Ratio Related Terms
Insight Molecular Diagnostics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Quick Ratio falls into.
Insight Molecular Diagnostics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Quick Ratio of 2.51 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Insight Molecular Diagnostics and its competitors. This is near median its historical median of 2.58. Over the past decade, Insight Molecular Diagnostics' Quick Ratio has ranged from 0.50 to 12.82. According to the industry distribution chart, Insight Molecular Diagnostics ranks #79 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 36.7%.
Is Insight Molecular Diagnostics' Quick Ratio too high?
Insight Molecular Diagnostics' current Quick Ratio of 2.51 is near median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 12.82. The Medical Diagnostics & Research industry median Quick Ratio is 1.67. Insight Molecular Diagnostics' value of 2.51 is 50.3% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #79 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Quick Ratio compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #79 out of 215 companies for Quick Ratio. This puts Insight Molecular Diagnostics in the upper half of its industry. The industry median Quick Ratio is 1.67. Insight Molecular Diagnostics' value of 2.51 is 50.3% above this benchmark. Historically, Insight Molecular Diagnostics' own Quick Ratio has ranged from 0.50 to 12.82 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 1.67, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.67, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Quick Ratio of 2.51 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Quick Ratio is 2.51, which is near median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.42 — trading 330.2% above its estimated fair value. The current Quick Ratio is 2.51, which is near median its 10-year median of 2.58 and 50.3% above the Medical Diagnostics & Research industry median of 1.67. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Quick Ratio is 2.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Quick Ratio: 2.51 (near median its 10-year median of 2.58)
GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
Industry Position: 50.3% above the Medical Diagnostics & Research median (#79 of 215)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
